Skip to content

MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria

MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03097250
Enrollment
10
Registered
2017-03-31
Start date
2017-10-25
Completion date
2018-07-01
Last updated
2018-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phenylketonuria

Keywords

PKU, Neuropsychology, MRI

Brief summary

This is a study about the relationship of brain biomarkers with neuropsychological functioning in PKU. All participants will undergo MRI spectroscopy, will provide a blood specimen and will receive neuropsychological testing.

Detailed description

Despite newborn screening and early initiation of treatment, many adolescents and adults with PKU experience some degree of neuropsychological dysfunction or mood disturbances. Blood phenylalanine (Phe) levels and low levels of tyrosine (Tyr) only partially explain why some individuals with PKU have these difficulties and others do not. In this study, the investigators will use a new approach involving magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) for measuring brain Phe (and other brain chemicals) in order to determine relationships between brain biomarkers and neuropsychological functioning and mood. Previously, brain Phe and Tyr could not be reliably measured by MRS methods, especially in concentrations likely to be found in individuals with treated PKU. This project will use an improved method for measuring brain Phe and Tyr. The investigators will use two-dimensional shift correlated magnetic resonance spectroscopy (COSY). COSY is a non-invasive method that allows for quantitative measurement of Phe, Tyr and other amino acids in the brain. This project has the potential to close one of the most important gaps in the knowledge of PKU, namely to define how PKU affects the brain. The aims of this study are to examine brain Phe and Tyr in individuals with PKU and in an age-matched healthy comparison group, and 2) determine the association of Phe and Tyr in distinct brain regions with measures of neuropsychological functioning and mood. Participants with PKU will receive 2 MRI scans with spectroscopy and the comparison group will receive 1 MRI scan with spectroscopy under fasting conditions. All participants will provide a blood specimen for blood amino acid determinations and will receive neuropsychological testing. The investigators will develop statistical models that can be applied in future studies to enhance understanding of PKU. This pilot study is important because it will provide evidence of the usefulness of COSY. COSY has the potential to explain individual differences in PKU, identify specific cognitive functions or mood disturbances related to high brain Phe or low brain Tyr, and offer an additional marker or endpoint for evaluating new treatments in clinical trials.

Interventions

None listed

Sponsors

Brigham and Women's Hospital
CollaboratorOTHER
Boston Children's Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 12-25 years 2. Not currently participating in a clinical trial 3. Capable of providing informed assent/consent 4. Able to undergo MRI procedures without sedation 5. Does not have metal implants (braces or permanent retainers made of MRI-compatible materials are permitted since we will not be doing procedures, such as DTI, affected by non-ferrous metals). 6. PKU Group: identified by newborn screening; received treatment within the first 30 days of life 7. PKU Group: Pre-treatment/off-diet blood Phe concentration at or above 600 umol/L

Exclusion criteria

1. Older than 25 years or younger than 12 years of age. 2. Currently participating in a clinical trial 3. Incapable of providing informed assent/consent 4. Pregnant women will be excluded 5. Not able to tolerate MRI procedures without sedation 6. Has metal implants or braces on teeth not compatible with MRI 7. Has any known contraindication for MRI 8. PKU Group: Pre-treatment/off-diet blood Phe concentration below 600 umol/L) 9. PKU Group: Not identified through newborn screening or treatment was initiated after 30 days of life

Design outcomes

Primary

MeasureTime frameDescription
Neuropsychological functioning1 dayNIH Toolbox Cognitive Battery
Social/Emotional Outcome1 dayNIH PROMIS Questionnaires (Neuro QoL)
Blood Biomarkers2 daysPhenylalanine and Tyrosine (umol/L)
Brain Biomarkers2 daysPhenylalanine and Tyrosine (umol/L)

Secondary

MeasureTime frameDescription
Intellectual Functioning1 dayFull Scale IQ

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026